Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Abstract Background The efficacy and safety of apremilast were assessed in patients with psoriatic arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3). Methods Following a 24-week, randomized (1:1:1 to apremilast 30 mg twice daily, 20 mg twice daily, or place...

Full description

Bibliographic Details
Main Authors: Arthur Kavanaugh, Dafna D. Gladman, Christopher J. Edwards, Georg Schett, Benoit Guerette, Nikolay Delev, Lichen Teng, Maria Paris, Philip J. Mease
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Arthritis Research & Therapy
Subjects:
Apremilast
Drug safety
Psoriatic arthritis
Treatment efficacy
Online Access:http://link.springer.com/article/10.1186/s13075-019-1901-3

Internet

http://link.springer.com/article/10.1186/s13075-019-1901-3

Similar Items